Considering the substantial residual risk for cardiovascular disease and kidney failure in individuals with T1D despite guideline‐directed therapy (Khunti et al., 2015; Lee et al., 2019), the use of SGLT2 inhibitors may improve the overall benefit–risk balance in patients with T1D. Here, SLC5A2 is linked to kidney failure.